The most commonly used drug in the treatment of women with hormone-dependent breast cancer is tamoxifen. A recent study addressed the issue of tamoxifen leading to a resistance against the drug by investigating the underlying mechanisms, utilizing a GPR30 antibody that is available at antibodies-online.

Continuous treatment of MCF-7 cells (breast cancer cell line) for six months led to resistance against tamoxifen. Similarly, continuous treatment with an agonist for the new estrogen G-protein coupled receptor GPR30 increases tamoxifen resistance. Hence, this data suggests that GPR30 receptor signaling is involved in the mediation of tamoxifen induced resistance against this anti-cancer drug.

antibodies-online.com offers a range of anti-GPR30 antibodies.